Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One-offs, probes and global economics mar results

This article was originally published in Clinica

Executive Summary

Alcon's sales growth was fuelled by its pharmaceuticals business: sales of surgical products rose by a modest 5.8% to $345m. The refractive business was hit by global economic conditions and weak consumer confidence but the company hopes the recent approval of its CustomCornea technology for wavefront-guided ablation will help improve sales. Nevertheless, it admits the business is likely to remain depressed in the current economic climate. Sales of intraocular lenses and of cataract and vitrectomy equipment, the two largest areas, both grew by more than 10%.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts